Research progress of glucocorticoid receptor in urological malignant tumors

Abstract

Zhou Qidong, Jiang Guangliang, Xu Ke. Research progress of glucocorticoid receptor in urological malignant tumors[J]. Journal of International Oncology, 2017, 44(6): 476-.

［1］王德杰, 刘兴国, 张东. 糖皮质激素受体的研究进展［J］. 现代生物医学进展, 2010, 10(8): 1592-1594. DOI: 10.13241/j.cnki.pmb.2010.08.001. ［2］ Stechschulte LA, Wuescher L, Marino JS, et al. Glucocorticoid receptor β stimulates Akt1 growth pathway by attenuation of PTEN［J］. J Biol Chem, 2014, 289(25): 17885-17894. DOI: 10.1074/jbc.M113.544072. ［3］ Nicolaides NC, Charmandari E, Chrousos GP, et al. Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids: novel mutations, circadian rhythm and ligandinduced repression of the human glucocorticoid receptor［J］. BMC Endocr Disord, 2014, 14: 71. DOI: 10.1186/147268231471. ［4］ Kassi E, Moutsatsou P. Glucocorticoid receptor signaling and prostate cancer［J］. Cancer Lett, 2011, 302(1): 1-10. DOI: 10.1016/j.canlet.2010.10.020. ［5］ McBeth L, Grabnar M, Selman S, et al. Involvement of the androgen and glucocorticoid receptors in bladder cancer［J］. Int J Endocrinol, 2015, 2015: 384860. DOI: 10.1155/2015/384860. ［6］ Czarnecka AM, Niedzwiedzka M, Porta C, et al. Hormone signaling pathways as treatment targets in renal cell cancer (review)［J］. Int J Oncol, 2016, 48(6): 2221-2235. DOI: 10.3892/ijo.2016.3460. ［7］ Yakirevich E, Matoso A, Sabo E, et al. Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study［J］. Hum Pathol, 2011, 42(11): 1684-1692. DOI: 10.1016/j.humpath.2011.01.014. ［8］ Min KJ, Jang JH, Lee JT, et al. Glucocorticoid receptor antagonist sensitizes TRAILinduced apoptosis in renal carcinoma cells through upregulation of DR5 and downregulation of cFLIP(L) and Bcl2［J］. J Mol Med (Berl), 2012, 90(3): 309-319. DOI: 10.1007/s0010901108218. ［9］ Jang JH, Min KJ, Kim S, et al. RU486 induces proapoptotic endoplasmic reticulum stress through the induction of CHOP expression by enhancing C/EBPδ expression in human renal carcinoma caki cells［J］. J Cell Biochem, 2016, 117(2): 361-369. DOI: 10.1002/jcb.25278. ［10］ Huynh TP, Barwe SP, Lee SJ, et al. Glucocorticoids suppress renal cell carcinoma progression by enhancing Na,KATPase beta1 subunit expression［J］. PLoS One, 2015, 10(4): e122442. DOI: 10.1371/journal.pone.0122442. ［11］ Arai Y, Nonomura N, Nakai Y, et al. The growthinhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro［J］. Cancer Invest, 2008, 26(1): 35-40. DOI:10.1080/07357900701638418. ［12］ Zheng Y, Izumi K, Li Y, et al. Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasonemediated glucocorticoid receptor signals［J］. Mol Cancer Ther, 2012, 11(12): 2621-2632. DOI: 10.1158/15357163.MCT120621. ［13］ Ishiguro H, Kawahara T, Zheng Y, et al. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity［J］. Cancer Chemother Pharmacol, 2014, 74(2): 249-255. DOI: 10.1007/s0028001424967. ［14］ Zheng Y, Ishiguro H, Ide H, et al. Compound A inhibits bladder cancer growth predominantly via glucocorticoid receptor transrepression［J］. Mol Endocrinol, 2015, 29(10): 1486-1497. DOI: 10.1210/me.20151128. ［15］ Lesovaya E, Yemelyanov A, Kirsanov K, et al. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies［J］. Cell Cycle, 2013, 12(1): 133-144. DOI: 10.4161/cc.23048. ［16］ Kashiwagi E, Fujita K, Yamaguchi S, et al. Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract［J］. Cancer Biol Ther, 2016, 17(11): 1188-1196. DOI: 10.1080/15384047.2016.1235667. ［17］ Ishiguro H, Kawahara T, Zheng Y, et al. Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression［J］. Am J Clin Pathol, 2014, 142(2): 157-164. DOI: 10.1309/AJCPU8UCEZYG4WTV. ［18］ McBeth L, Nwaneri AC, Grabnar M, et al. Glucocorticoid receptor beta increases migration of human bladder cancer cells［J］. Oncotarget, 2016, 7(19): 27313-27324. DOI: 10.18632/oncotarget.8430. ［19］ Nwaneri AC, McBeth L, Hinds TD Jr. SweetP inhibition of glucocorticoid receptor β as a potential cancer therapy［J］. Cancer Cell Microenviron, 2016, 3(3). pii: e1362. ［20］ Hu J, Chen Q. The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside［J］. Int Urol Nephrol, 2016, 49(3): 369-380. DOI: 10.1007/s1125501614768. ［21］ Isikbay M, Otto K, Kregel S, et al. Glucocorticoid receptor activity contributes to resistance to androgentargeted therapy in prostate cancer［J］. Horm Cancer, 2014, 5(2): 72-89. DOI: 10.1007/s1267201401732. ［22］ Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade［J］. Cell, 2013, 155(6): 1309-1322. DOI: 10.1016/j.cell.2013.11.012. ［23］ Xie N, Cheng H, Lin D, et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors［J］. Int J Cancer, 2015, 136(4): E27-E38. DOI: 10.1002/ijc.29147. ［24］ Kach J, Conzen SD, Szmulewitz RZ. Targeting the glucocorticoid receptor in breast and prostate cancers［J］. Sci Transl Med, 2015, 7(305): 305ps19. DOI: 10.1126/scitranslmed.aac7531. ［25］ Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer［J］. Sci Transl Med, 2014, 6(254): 254ra125. DOI: 10.1126/scitranslmed.3009448.

[1]	Zhao Xin, Fan Xuewu, Tian Long, Hu Yimin.Application and evaluation study of 3D ultrasound in image guided radiotherapy for prostate cancer[J]. Journal of International Oncology, 2024, 51(1): 43-49.
[2]	Qian Weiwei, Xu Shen, Kong Qi.Differential diagnosis value of D-dimer before operation in renal oncocytoma and chromophobe renal cell carcinoma[J]. Journal of International Oncology, 2023, 50(10): 614-617.
[3]	Xu Xi, Gao Hongliang, Liu Xiang, Zhang Zhensheng, Xu Chuanliang.Correlations between different pH values in tumor microenvironment and bladder cancer[J]. Journal of International Oncology, 2022, 49(11): 696-609.
[4]	Wang Ziyi, Chen Hongjie, Yang Ninggang, Zhang Jun, Zhang Xiangjun, Yu Xinning, Ma Zhongyi, Dai Enlai.Effects of decorin on proliferation, migration and invasion of bladder cancer cells[J]. Journal of International Oncology, 2021, 48(6): 335-340.
[5]	Du Xiao, Zhou Juying.Stereotactic body radiotherapy for localized prostate cancer[J]. Journal of International Oncology, 2021, 48(5): 313-316.
[6]	Zhang Xiaofei, Hu Jianpeng, Cui Feilun.Mechanism of long non-coding RNA in prostate cancer[J]. Journal of International Oncology, 2021, 48(2): 117-120.
[7]	Wu Guang, Yu Yuandong, Chen Ping.Clinical observation of apatinib mesylate in the treatment of metastatic renal carcinoma[J]. Journal of International Oncology, 2021, 48(11): 655-659.
[8]	Wang Jiali, Han Dong, Chen Ying, Zhang Yamin, Ai Meimei.Construction of a nomogram of overall survival of patients with clear cell renal cell carcinoma based on preoperative CT findings[J]. Journal of International Oncology, 2020, 47(8): 480-486.
[9]	Ji Chundong, Liu Kai, Feng Yue, Wang Fei, Yang Jun, Xue Rongbo.Predictive value of PSAMR combined with PI-RADS v2 score in high-grade prostate cancer[J]. Journal of International Oncology, 2020, 47(12): 723-727.
[10]	Han Jing, Yuan Shuai, Pu Yan, Liu Huibin.Analysis of SKA1 gene expression in clear cell renal cell carcinoma and its clinical significance based on bioinformatics database[J]. Journal of International Oncology, 2020, 47(10): 598-605.
[11]	Zhang Jiawei, Wu Jianchen.Application of exosomes in prostates cancer[J]. Journal of International Oncology, 2020, 47(10): 634-636.
[12]	Chen Liang, Peng Min, Weng Yiming, Song Qibin.New strategies for the treatment of clear cell renal cell carcinoma: target the metabolic reprogramming[J]. Journal of International Oncology, 2019, 46(7): 443-446.
[13]	Xiong Bobo, Zhang Jinsong, Li Ning, Wang Haifeng, Zuo Yigang, Wang Jiansong.Molecular targeted therapy for advanced kidney cancer[J]. Journal of International Oncology, 2019, 46(12): 705-710.
[14]	Cai Liang, Shen Yali. Application of stereotactic body radiation therapy in advanced renal cell carcinoma[J]. Journal of International Oncology, 2019, 46(10): 627-630.
[15]	XU Yao-Zong, GU Xiao, WANG Fei, DING Xue-Fei.Molecular mechanisms of castrationresistant prostate cancer progressed from prostate cancer by androgen deprivation treatment[J]. Journal of International Oncology, 2018, 45(8): 506-509.

Research progress of glucocorticoid receptor in urological malignant tumors

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments